Investors Watch List: Kinross Gold Corporation (NYSE:KGC), Yahoo! Inc. (NASDAQ:YHOO), Kaman Corporation (NYSE:KAMN), Opko Health, Inc. (NYSE:OPK), FleetCor Technologies, Inc. (NYSE:FLT)

On 29 July, Kinross Gold Corporation (NYSE:KGC) announced its results for the second quarter ended June 30, 2015. Revenue from metal sales was $755.2 million in Q2 2015, compared with $911.9 million during the same period in 2014, primarily due to a lower average realized gold price and lower gold equivalent ounces sold as a result of timing of sales. Kinross Gold Corporation (NYSE:KGC) belongs to Basic Materials sector. Its net profit margin is -40.60% and weekly performance is 2.20%. On last trading day company shares ended up $1.86. Kinross Gold Corporation (NYSE:KGC) distance from 50-day simple moving average (SMA50) is -12.80%.

On 4 August, Yahoo! Inc. (NASDAQ:YHOO) said it agreed to buy fashion startup Polyvore to help drive traffic and strengthen its mobile and social offerings. Yahoo! Inc. (NASDAQ:YHOO) shares increased 0.58% in last trading session and ended the day at $36.67. YHOO Gross Margin is 66.70% and its return on assets is 12.60%. Yahoo! Inc. (NASDAQ:YHOO) quarterly performance is -16.83%.

Investment analysts at KeyBanc started coverage on shares of Kaman Corporation (NYSE:KAMN) in a note issued to investors on Tuesday. The firm set a “sector weight” rating on the stock. On 07 August, Kaman Corporation (NYSE:KAMN) shares decreased -0.03% and was closed at $39.57. KAMN EPS growth in last 5 year was 19.60%. Kaman Corporation (NYSE:KAMN) year to date (YTD) performance is -0.46%.

On 5 August, Opko Health, Inc. (NYSE:OPK) announced that additional data from OPKO’s hGH-CTP pediatric Phase 2 clinical trials summarized in two abstracts entitled, “12 month Safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) compared to daily recombinant human GH (rh)GH) therapy in pre-pubertal growth hormone deficient children; Phase 2 study – Study CP-4-004 Summary” and “Pharmacokinetic (PK) and Pharmacodynamics (PD) Modeling of MOD 4023 (a long-acting human growth hormone (hGH)) in Growth Hormone Deficient (GHD) Children” has been selected for oral presentation at the upcoming 54th Annual Meeting of the European Society for Paediatric Endocrinology taking place in Barcelona, Spain from October 1-3.Opko Health, Inc. (NYSE:OPK) ended the last trading day at $13.76. Company weekly volatility is calculated as 5.88% and price to cash ratio as 18.31. Opko Health, Inc. (NYSE:OPK) showed a weekly performance of -15.94%.

On 5 August, FleetCor Technologies, Inc. (NYSE:FLT) reported financial results for its second quarter ended June 30, 2015. GAAP net income 1 increased to $98.7 million or $1.05 per diluted share in the second quarter of 2015 compared to GAAP net income of $88.5 million or $1.03 per diluted share in the second quarter of 2014.FleetCor Technologies, Inc. (NYSE:FLT) shares increased 0.62% in last trading session and ended the day at $160.00. FLT Gross Margin is 92.20% and its return on assets is 6.00%. FleetCor Technologies, Inc. (NYSE:FLT) quarterly performance is 3.35%.

Leave a Reply

Your email address will not be published. Required fields are marked *